Dell Technologies HPC Community Event
HPC and accelerator-driven computing have become pivotal to drive research in Pharma. Where 5 years ago less than 1% of the researchers actively used HPC resources, AstraZeneca is driving a clear strategy to gain the majority of insights by 2025 through data and AI. This ambition is leading to a constant change in how our researchers work and are presenting an unstoppable appetite for computing.
We will discuss the journey of the last 5 years renewing the approach we are taking towards high-performance computing, explore use cases that are leveraging compute in significantly different ways, driving our research in innovative ways, and share an outlook and vision into our future direction.